OpenAI Buys Orchestra Bio As GPT-Rosalind Agents Find A New Lead In Neurodegeneration
0:00 / 0:43
News
OpenAI Buys Orchestra Bio As GPT-Rosalind Agents Find A New Lead In Neurodegeneration
calendar_today Date:
schedule Duration: 0:43
database
Summary Report
OpenAI acquired Orchestra Bio for Rosalind, and GPT-Rosalind agents proposed a testable mechanism for Perry syndrome.
- 01. Orchestra Bio's drug-development agents join OpenAI's Rosalind suite
- 02. Thousands of GPT-Rosalind agents linked mouse brain-cell data to literature in 32 minutes
OpenAI has acquired Orchestra Bio, a startup whose agents help biopharma teams coordinate drug development by monitoring studies, tracking timelines and flagging delays. The team joins Rosalind, OpenAI's life-sciences suite. With Perturb and Scripps Research, thousands of GPT-Rosalind agents connected gene-expression data from millions of mouse brain cells with the literature, suggesting that in Perry syndrome cholesterol may not be reaching the neurons that need it, a mechanism scientists can now test.
Meta Data
Company:
LLM:
Model:
